Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	224.67M
Revenue (ttm)	196.49M
Net Income (ttm)	-259.47M
Shares Out	68.08M
EPS (ttm)	-3.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	478,542
Open	3.520
Previous Close	3.520
Day's Range	3.280 - 3.580
52-Week Range	1.575 - 19.950
Beta	-0.54
Analysts	Buy
Price Target	7.60 (+130.3%)
Earnings Date	Mar 4, 2025

About AMLX

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 384
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Forecast

According to 7 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is $7.6, which is an increase of 130.30% from the latest price.

Price Target

$7.6

(130.30% upside)

Analyst Consensus: Buy